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Introduction: Cross-sectional studies document that the spot protein/creatinine ratio (PCR) is often an
inaccurate estimate of proteinuria magnitude compared with the 24-hour PCR, which is the gold standard.
However, the extent to which the inaccuracy of the spot PCR varies over time and between individuals has
not previously been reported. We address these crucial questions using a unique database, an National
Institutes of Health trial in which lupus nephritis (LN) patients (N ¼ 103) provided spot PCR testing each
month and 24-hour PCR testing every 3 months for up to 15 months after induction therapy.
Methods: A gold standard proteinuria trend line was constructed for each patient by joining the points that
represented the serial 24-hour PCR values of the patient. The spot PCR values of the patient were then
plotted in relationship to the 24-hour PCR trend line. Using our previous work, which estimated the 95%
conﬁdence intervals for the 24-hour PCR at speciﬁc levels, we determined in each patient whether the spot
PCR values were “reliable,” “problematic,” or “unreliable.” The sequential spot PCR of the patients
deviated widely and often from the 24-hour PCR trend line, to the extent that, if the spot PCR results were
used in real time for clinical decision-making, it was likely management errors would occur.
Results: Spot PCRs were reliable in 41%, problematic in 24%, and unreliable in 35% of patients. Those with
unreliable spot PCRs could not be predicted and were more likely to respond poorly to treatment.
Conclusion: The spot PCR should not be used for management of LN, and perhaps, other
glomerulopathies.
Kidney Int Rep (2018) 3, 1057–1063; https://doi.org/10.1016/j.ekir.2018.04.010
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he protein/creatinine ratio (PCR) of a spot (single
void) collection is the method for monitoring proteinuria currently recommended by Kidney Disease
Improving Global Outcomes and by the American College of Rheumatology.14 The basis for this recommendation is that spot collections are convenient for the
patient and the physician, and produce a PCR value that
is signiﬁcantly correlated with 24-hour proteinuria
(24-hour P). However, as previously discussed,5,6 the
high correlation coefﬁcients between the spot PCR and
24-hour P (e.g., typically >0.90) is a mathematical consequence of comparing the spot PCR and 24-hour P over a
wide range of values (e.g., 24-hour P range: 0– 10 g/d).
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Over more restricted ranges (e.g., subnephrotic range
proteinuria, #3.5 g/d, the most common range of
abnormal proteinuria), the correlation coefﬁcient between the spot PCR and 24-hour P is weak, and concordance is poor.511
The reason for the poor correlation and concordance
between the spot PCR and 24-hour P (or 24-hour PCR)
is the remarkable variability of the spot PCR. This was
ﬁrst demonstrated by Koopman in patients with
nephrotic range proteinuria, who were placed at complete bedrest for 3 days, maintained on a constant diet,
and received no medications. Despite these measures
intended to stabilize proteinuria, the PCR of sequential
3-hour urine collections over 3 days was highly
variable. For example, the spot PCR ranged from
approximately 3.0 to 9.0.5 Because of this inherent
hour-to-hour variability of the PCR, short urine collections (e.g., spot collections) revealed this PCR
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variability, whereas long collections (e.g., intended 24hour urine collections) concealed this PCR variability
because the PCR of a long collection is the integrated
mean of the PCRs of the entire collection.5,8
As we and others have shown, it is not necessary to
obtain a complete 24-hour collection to reliably determine the 24-hour PCR. Rather, it is sufﬁcient that the
intended 24-hour urine collection represents a substantial fraction of a complete 24-hour collection. For
example, 50% of a complete collection, based on its
creatinine content, provides a PCR that is a reliable
estimate of the PCR of a complete 24-hour urine collection in that patient.6,12 For our previously published
comparisons, the deﬁnition of a “complete” 24-hour
urine collection is the creatinine content of the collection within 10% of that calculated from the CockcroftGault equation and solved to estimate 24-hour creatinine
excretion.6,13
The use of spot PCRs in research is generally not
problematic because much of the spot PCR variability is
random. So, in comparing spot PCR values among cohorts, the random variability within each cohort is offset
by averaging. However, in the management of individual
patients, the remarkable variability of spot PCRs could
lead to serious errors in management. The present work is
the ﬁrst to rigorously examine this question. We studied
patients with lupus nephritis (LN) who received induction therapy in the ACCESS (Abatacept and Cyclophosphamide Combination Efﬁcacy and Safety Study) trial.14
By protocol, each patient provided a 24-hour urine
collection every 3 months and a spot urine collection
monthly, for up to 15 months of follow-up. A proteinuria
trend line was constructed for each patient by joining the
24-hour PCR points. This line was deemed the most reliable measure of the proteinuria trend. The rationale was
that 24-hour PCR (or 24-hour P) was the most reliable
estimate of the proteinuria magnitude.5,6,912 Therefore,
the line created by joining the individual 24-hour PCR
values is the most reliable estimate of the proteinuria
trend. The individual spot PCR values of the patients
were compared with this trend line. ACCESS was well
suited for this analysis because spot and 24-hour urine
collections were made at prespeciﬁed intervals in a large
group of patients whose proteinuria changed over a wide
range of values during 15 months of follow-up.
METHODS
ACCESS was a phase II multicenter, randomized,
double-blind controlled trial of abatacept versus placebo with a standard care low-dose i.v. cyclophosphamide in patients with class III or IV LN.14 By
protocol, each patient provided a single freshly voided
spot urine collection at each of the monthly study
1058
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visits. At the 3-, 6-, 9-, and 12-month visits, only a 24hour urine collection was provided.
Determining the Ability of the Spot PCR to
Reliably Identify Proteinuria Trends During
ACCESS Follow-up
For this analysis, the sequential spot PCR values for
each patient were displayed graphically over time and
in relation to the proteinuria trend line of the patient
(sequential 24-hour PCR values). Supplementary
Figure S1 illustrates this for each patient according
to whether the spot PCRs were determined to be
reliable, problematic (generally reliable but with
notable exceptions), or unreliable in identifying the
proteinuria trends of the patients as deﬁned by the 24hour PCR trend line. These adjudications were a 2-step
process carried out concurrently by co-authors GS,
DB, and LH. Step 1 involved the inspection of the spot
PCR/24-hour PCR graph of each patient to determine
whether it was empirically evident (obvious) that the
spot PCR/24-hour PCR met the criteria for reliable spot
PCR. The spot PCR values closely followed the 24-hour
PCR trend line and would inform clinical decisionmaking, as well as the 24-hour PCR values. The
cases that did not have a reliable spot PCR were
evaluated in step 2.
Step 2 objectively measured the frequency of when
the spot PCR values of the patient were outside the
95% conﬁdence intervals (CIs) of the corresponding 24hour PCR values, which were extrapolated from the 24hour PCR trend line of the patient. The extrapolation
was performed as follows. For each spot PCR value that
deviated widely from the 24-hour PCR trend line of the
patient, a perpendicular extrapolation was made from
that spot PCR value to the 24-hour PCR trend line of
the patient. To assess whether the spot PCR value was
outside of the 95% CIs of the extrapolated 24-hour
PCR, we used our previous work, which calculated
the 95% CIs for speciﬁc levels of 24-hour PCR in LN
patients who were followed long-term and had stable 24-hour PCR at prespeciﬁed levels.15 To determine
whether the spot PCRs were outside of the 95% CIs of
the extrapolated 24-hour PCRs, we selected the 24-hour
PCR range that included the spot PCR of interest from
our previously published work. If the spot PCR of interest was outside the 95% CIs of the 24-hour PCR
range to which it was matched, the spot PCR was
deemed an outlier that contributed to the determination of whether the spot PCR of the patient was
problematic or unreliable. For the determination of spot
PCR reliability and/or unreliability, we did not
construct 95% CIs bands for spot PCRs of individual
patients because there were too few spot PCR measurements per patient.
Kidney International Reports (2018) 3, 1057–1063
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Depending on the number and pattern of spot PCRs
that deviated widely from the 24-hour PCR trend line
of the patient, we deﬁned 2 different degrees of spot
PCR unreliability as follows.
Spot PCR is generally reliable but with notable exceptions (problematic). In these cases, 1 or 2 spot PCR
values showed large deviations (outside of the 95% CIs)
from the 24-hour PCR trend line. Because these deviations were large, it was likely that they would be
problematic for the managing physician because these
spurious spot PCR values unfolded in real time.
The spot PCR is unreliable. In these cases, spot PCR
was deemed obviously unreliable either because of $3
large, usually sequential (>1.96 SD, the 95% CI) deviations of the spot PCR from the 24-hour PCR trend
line or a single large spike in the spot PCR from the 24hour PCR trend line that was consistent with a highthreshold criteria (HTC) (using the most stringent of
the HTC criteria) proteinuric ﬂare.15
To provide further detail regarding the rationale for
the unreliable spot PCR classiﬁcations, in Supplementary
Figure S1, each of the unreliable spot PCR/24-hour PCR
graphs (N ¼ 36) is annotated, and the spot PCRs that
determined the unreliable classiﬁcation are cited.
Thresholds for Proteinuria LN Flare
In previous work, we discussed investigators who used
different thresholds to deﬁne a LN proteinuric ﬂare.
We categorized these as low-threshold criteria,
intermediate-threshold criteria, or HTC. Examples of
HTC for LN proteinuric ﬂares would be a preﬂare 24hour PCR $2.0 that increased by $100%.15 It is
these HTC that we used to determine whether a given
spot PCR represented a large deviation from the 24hour PCR trend line of the patient.
Statistical Analysis
Normally distributed variables are shown as the mean
value  SD. Other variables are shown as the median
and interquartile range. The statistical tests used in
these comparisons are shown in relationship to the
data.
RESULTS
ACCESS demographics and baseline clinical characteristics have previously been reported.14 The ACCESS
cohort is representative of US LN cohorts because most
are female and many are of African ancestry.
Ability of the Spot PCR to Correctly Identify the
Proteinuria Trend
For this analysis, 103 patients were eligible based on
having at least 3 24-hour PCR measures during the
interval that the monthly spot PCRs were measured.
Kidney International Reports (2018) 3, 1057–1063
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Each sequential spot PCR values of the patients were
displayed in relationship to the proteinuria trend line
of that patient (the line formed by joining the
sequential 24-hour PCR values of the patient). The
outcome was that spot PCRs were found to be reliable
in 41% (42 of 103), problematic in 24% (25 of 103), and
unreliable in 35% (36 of 103) of patients.
Figure 1 shows the spot PCR/24-hour PCR displays
for 5 representative reliable patients matched to 5
representative unreliable patients based on the 24-hour
PCR at baseline. The unreliable patients were also
selected because their values illustrated that unreliable
spot PCRs could greatly and consistently overestimate
or underestimate the 24-hour PCR trend line, and
included those in whom the spot PCR trend was
opposite to that of the 24-hour PCR trend line.
Supplementary Figure S1 shows the spot PCR/24hour PCR display for each patient. The displays are
arranged in cohorts (reliable, problematic, and unreliable). The unreliable spot PCRs/24-hour PCRs displays
are annotated, and the spot PCRs responsible for the
unreliable classiﬁcation are cited.
Association of Demographic and Baseline
Clinical Measures With the Reliable,
Problematic, or Unreliable Classiﬁcations
To assess whether baseline measures could predict
whether the spot PCR would be reliable, problematic,
or unreliable, we performed univariate assessment of
key demographic and baseline clinical measures. As
shown in Table 1, this exploratory analysis did not
identify predictors of reliability and/or unreliability.
The ACCESS ﬁnal outcomes of complete remission
(CR), partial remission (PR), or treatment failure (TF)
were associated with whether the spot PCRs of the
patients during ACCESS were classiﬁed as reliable,
problematic, or unreliable. This analysis involved the
98 ACCESS patients who had $3 24-hour PCR measures
and accompanying spot PCR measures (this determined
whether their spot PCRs were reliable, problematic, or
unreliable). Baseline and ﬁnal 24-hour PCR measurements were assessed (this determined whether the ﬁnal
outcomes of the patient were CR, PR, or TF). As shown
in Figure 2, according to the c2 test, the cohort with
unreliable spot PCR was more likely to have experienced TF and less likely to have experienced CR,
compared with the cohort whose spot PCRs were reliable (P ¼ 0.032), or compared with the combined cohorts of reliable and problematic PCRs (P ¼ 0.024).
DISCUSSION
It is well established that spot PCR testing often produces a highly variable estimate of 24-hour P or 24-hour
PCR.6,811 This is most clearly shown in calibration plots
1059
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Figure 1. Representative ACCESS patients in whom the spot protein/creatinine (P/C) ratio (PCR) was deemed to be reliable or unreliable based
on the degree to which the spot PCR values of the patient follows the proteinuria trend line of the patient (the line joining the patient’s 24 PCR
value). See Supplementary Figure S1 for display of all 103 ACCESS patients according to whether the spot PCRs were deemed reliable,
problematic, or unreliable.
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Table 1. Relationship between baseline measures and their association with whether the spot protein/creatinine ratio were deemed to be
reliable, problematic, or unreliable
Demographic

Reliable

Sex (F/M)

Weight (kg)b
Serum albumin (g/dl)

b

Serum creatinine(mg/dl)b
24-hour PCRb

Unreliable

P value
NDa

39/3

23/2

32/4

22/20/0

6/16/3

12/17/7

NDa

29.5 (25.037.0)

28.0 (24.526.5)

32 (25.045.0)

0.400c

72.0 (64.188.5)

62.1 (51.481.0)

70.6 (63.179.4)

0.089c

Race (B/W/O)
Age (yr)b

Problematic

2.9 (2.63.3)

2.7 (2.23.2)

2.7 (2.13.4)

0.181d

0.94 (0.701.20)

0.78 (0.601.38)

1.00 (0.801.24)

0.158c

2.3 (1.33.3)

3.5 (2.15.9)

2.3 (1.65.6)

0.046c

18/24

15/10

19/17

0.376a

22

—

21

0.652a

Abatacept/placebo
ACE inhibitor and/or ARB

ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; B/W/O, black, white, other race; ND, analysis not performed due to insufﬁcient sample size; PCR, protein/
creatinine ratio.
a
By Fisher exact test.
b
Median (intraquartiles).
c
By Kruskal-Wallis test.
d
By 1-way analysis of variance.

from cross-sectional studies in which a gold standard
estimate of 24-hour P (24-hour PCR) is displayed in
relationship to the ratio: spot PCR/24-hour PCR.6,8,9 In
these studies, spot PCRs were determined in morning
collections provided at the time of the clinic visit of the
patient, which was a morning visit.6,8,9,12 Based on these
cross-sectional studies, it could be anticipated that if the
30
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Figure 2. Outcome of induction therapy deﬁned as complete
remission (CR), partial remission (PR), or treatment failure (TF) according to whether the spot protein/creatinine ratio (PCR) of the
patient during induction therapy were reliable, problematic, or unreliable. As shown, those with unreliable spot PCRs were signiﬁcantly less likely to have achieved CR and signiﬁcantly more likely to
have TF compared with those whose spot PCRs were reliable (P ¼
0.032), or compared with the combined cohort of reliable þ generally
reliable (P ¼ 0.024).
Kidney International Reports (2018) 3, 1057–1063

spot PCR is used to guide clinical management, serious
errors could occur because of the marked variability of
the spot PCR estimate of the 24-hour PCR. However,
what could not be determined from previous work was
whether spot PCR unreliability was a pervasive problem
or conﬁned to certain individuals. The present work was
the ﬁrst to use the spot PCR to test this. This test was in
the context of the 103 ACCESS patients who provided
concurrent spot and 24-hour urine collections up to 15
months of follow-up in this prospective, placebocontrolled, double-blinded randomized trial of abatacept in patients with World Health Organization class III
or IV LN.14
We found that when spot PCRs were examined in
individual patients and over time, 3 distinct patterns
emerged: spot PCRs that were either reliable, problematic (generally reliable but with notable exceptions),
or unreliable. Most of the LN patients were in the
problematic and unreliable categories.
A unique strength of the present work was that the
comparison of the spot PCR to the 24-hour PCR was
longitudinal and involved multiple measurements per
patient. Previous similar studies involved only a few
PCR measurements per patient.1618 Therefore, in the
present work, it was possible to determine how the
variability of spot PCRs compared with that of 24-hour
PCRs over time, over a wide range of spot PCR and 24hour PCR values, and from patient to patient.
A limitation of the present work was that, according to
the ACCESS protocol, the comparison of the spot PCR to
the 24-hour PCR trend line was not the result of spot and
24 hour urine collections made on the same day. However, we suggest that this concern did not invalidate our
conclusions. Three independent studies in which spot
PCR and 24-hour PCR were compared “head to head”
already showed that the spot PCR is a highly unreliable
estimate of the 24-hour PCR.8,9 The present work simply
1061
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conﬁrmed the unreliability, and, most importantly,
showed for the ﬁrst time that being classiﬁed as unreliable
is a characteristic of a subset of patients.
In performing our analysis of spot PCR variability,
we did not use correlational analyses such as BlandAltman or a calibration plot. This would have
obscured the fact that unreliable spot PCRs belong only
to a subset of the patients.
Our case-by-case analysis of the metrics of unreliable
spot PCRs showed that the degree of unreliability
varied widely not only from patient to patient, but also
within patients. For example, it was common for the
patients who were classiﬁed as unreliable patients to
manifest unreliable spot PCRs for $3 months. This
means that, if a dubious spot PCR was encountered, the
strategy of simply repeating a spot PCR in the hope that
it would “regress to the mean” would not be a
consistent winning strategy. Also, we showed that the
amount by which the spot PCRs either overestimated or
underestimated 24-hour PCR was large and could easily
confound management. This was simulated in the
following scenarios.
Scenario 1 describes a patient in whom serial spot
PCRs showed dramatic improvement in proteinuria,
and the improvement was consistent for $3 consecutive months (see Figure 1, Unreliable cases 1, 3, 5). On
this basis, the managing clinician decided to more
rapidly taper therapy and change follow-up from
monthly to bimonthly. This could result in LN relapse,
which would not be discovered until >5 months later.
This mismanagement likely would have been avoided if
the patient had been monitored with 24-hour PCR.
Scenario 2 describes a patient in whom serial spot PCRs
showed dramatic worsening, which continued for 3 or 4
months (see Figure 1, cases 2, 4). On this basis, the managing clinician decided to intensify therapy. This would
needlessly expose the patients to the risks of excessive
immunosuppressive and glucocorticoid therapy.
With regard to the mechanism of spot PCR variability, Koopman showed that the changes in the spot
PCRs are related to changes in the protein excretion
rate, not the creatinine excretion rate. Also, Koopman’s
patients did not receive medications, were on a constant diet, and at complete bed rest. Therefore, unreliable spot PCRs are not explained by steroid or other
therapy, diet, or exercise. Also, ACCESS was a multicenter trial with a standard protocol for specimen
collection and handling, and a central laboratory for
testing. Finally, spot PCR results are regarded as independent of whether the specimen is concentrated or
diluted, because any change in urine volume will affect
the concentration of urine protein and creatinine proportionately. Therefore, these factors did not explain
spot PCR variability.
1062
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The key ﬁnding of this work is that unreliable and/
or problematic spot PCRs are a characteristic of a large
subset of patients. The combined problematic and unreliable cohorts made up the majority of the patients in
the ACCESS trial.
We suggest that the present work made a strong case
that LN patients should be followed with 24-hour PCR
testing, not spot PCR testing. The key arguments
include:
(i) There is no way to predict whether spot PCR results will be unreliable in a given patient.
(ii) It is a ﬂawed strategy to simply repeat the spot PCR
if spot PCR testing provides a dubious result (see
Supplementary Figure S1).
(iii) The informed LN patient would not wish to be
exposed to the risks described in Scenarios 1 and 2,
simply to avoid the inconvenience of an intended
24-hour urine collection.
(iv) Repeat spot testing is not simple. The logistics (loss of
work, and need for child care, travel, parking, and so
on) are complex, and often result in long delays.
(v) It is a common misconception that urine collections
need to be refrigerated15,1921 and that spot PCR
testing is less expensive than 24-hour PCR testing.
Neither is true. However, some laboratories do
charge for handling the 24-hour urine container.
(vi) Intended 24-hour urine collections provide valuable information on nutrient management, particularly sodium, potassium, and protein intake,
which cannot be reliably obtained by spot urine
testing.1921
An alternative to intended 24-hour urine collections
is a ﬁrst morning void that represents a complete
overnight collection. This underestimates PCR by
approximately 20%.12 Of greater concern is that an
overnight collection is a relatively short collection, so it
is more susceptible to variability. For example, variations in the diet of the patient (the evening meal is high
in salt and/or protein), variations in depth of sleep, or
the occurrence of nocturia might substantially affect
the PCR of an overnight collection. Also, contamination
of urine with semen, which has a high albumin concentration, is a potential source of variability in urine
protein in a ﬁrst morning void collection.8
In summary, clinical decisions in LN patients should
not rely on spot PCR testing. The preferred method is
an intended 24-hour urine collection that is at least
50% complete based on its creatinine content. Whether
these recommendations apply to other glomerulopathies remains to be determined.
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